Victoza should be protected from excessive heat and sunlight
Glucagon and glucagon-like peptide-1 dual agonist therapy: a possible future towards fatty kidney disease
According to the FDA's official guidance (updated April 2026 at fda.gov), the semaglutide injection shortage was resolved on February 21, 2025, and the transitional exemption windows for compounders operating under the shortage exemption subsequently ended - for 503A pharmacies by April 22, 2025, and for 503B outsourcing facilities by May 22, 2025
Both medications share a similar side effect profile primarily gastrointestinal
Angarita SAK, Duarte S, Russell TA, et al
On GLP-1 medications like semaglutide and tirzepatide, preserving muscle matters